Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L WATT

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
Nature Communications|May 15, 2021
Submarine landslide megablocks show half of Anak Krakatau island failed on December 22nd, 2018J E Hunt, D R Tappin, S F L Watt, et al.
Neurobiology of Disease|September 12, 2021
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathyMali Cosden, Sarah Jinn, Lihang Yao, et al.
British Journal of Cancer|September 12, 2013
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancerR K Kelley, J Hwang, M J M Magbanua, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Science Translational Medicine|October 8, 2010
PGC-1α, a potential therapeutic target for early intervention in Parkinson's diseaseBin Zheng, Zhixiang Liao, Joseph J Locascio, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
Nature Communications|May 15, 2021
Submarine landslide megablocks show half of Anak Krakatau island failed on December 22nd, 2018J E Hunt, D R Tappin, S F L Watt, et al.
Neurobiology of Disease|September 12, 2021
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathyMali Cosden, Sarah Jinn, Lihang Yao, et al.
British Journal of Cancer|September 12, 2013
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancerR K Kelley, J Hwang, M J M Magbanua, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Science Translational Medicine|October 8, 2010
PGC-1α, a potential therapeutic target for early intervention in Parkinson's diseaseBin Zheng, Zhixiang Liao, Joseph J Locascio, et al.
Pageof 18